Denmark based pharmaceutical firm Novo Nordisk today launched it’s combination diabetic drug Ryzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.
Apart from India, Ryzodeg has been approved for marketing in Aruba, Brazil, Chile, Costa Rica, El Salvador, EU, Hong Kong, Iceland, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland, Novo Nordisk said.
Novo Nordisk Corporate VP for Business Area Africa, Gulf & India, Mads Bo Larsen said: “India has close to 65.1 million people with diabetes standing second in the world map….We are extremely pleased to have introduced Ryzodeg reinforcing our commitment to provide best of healthcare solutions for the use of doctors in India.”
Courtesy: Economic Times. Read full article.